Heartport roll-out disappoints analyst as company moves to cut staff by a third
This article was originally published in Clinica
Executive Summary
The most recent quarterly financial results from Heartport, the company producing tools and techniques for minimally-invasive coronary surgery under the Port-Access name, have prompted adverse comments from investment analysts at Morgan Stanley Dean Witter.